DJIA39760.08 477.75
S&P 5005248.49 44.91
NASDAQ16399.52 83.82
Russell 20002116.20 44.40
German DAX18475.06 75.83
FTSE 1007931.98 1.02
CAC 408204.81 20.06
EuroStoxx 505082.75 17.40
Nikkei 22540762.73 364.70
Hang Seng16392.84 -225.48
Shanghai Comp2993.14 -38.34
KOSPI2755.11 -1.98
Bloomberg Comm IDX98.31 -0.37
WTI Crude-fut85.88 0.20
Brent Crude-fut81.35 -0.26
Natural Gas1.69 -0.02
Gasoline-fut2.69 0.01
Gold-fut2217.80 5.60
Silver-fut24.56 -0.13
Platinum-fut908.10 -1.80
Palladium-fut1002.00 6.50
Copper-fut399.40 -1.60
Aluminum-spot1815.00 0.00
Coffee-fut188.40 -2.25
Soybeans-fut1188.25 -4.25
Wheat-fut547.00 -0.50
Bitcoin70641.00 1575.00
Ethereum USD3585.86 110.25
Litecoin95.55 0.42
Dogecoin0.20 0.01
EUR/USD1.0814 -0.0015
USD/JPY151.42 0.09
GBP/USD1.2635 0.0016
USD/CHF0.9057 -0.0003
USD IDX104.69 0.32
US 10-Yr TR4.222 0.026
GER 10-Yr TR2.316 0.024
UK 10-Yr TR3.965 0.035
JAP 10-Yr TR0.716 -0.006
Fed Funds5.5 0
SOFR5.32 0.01

Connect Money In Your Inbox.

Sign up to get the most important news on the business of financial services delivered daily.

Sub Markets

Property Sectors

Topics

Alternative Assets  | 
Syneos Health Signs Multiyear Partnership with Microsoft to Use AI Technology

Syneos Health Signs Multiyear Partnership with Microsoft to Use AI Technology

Syneos Health has signed a multiyear deal with Microsoft to use its artificial intelligence technologies. Financial details and the length of the contract weren’t disclosed.

North Carolina-based Syneos secured the agreement to use its Microsoft Azure services, which has been using an analytics platform and machine learning to support its efforts in clinical trials and commercial programs.

“Microsoft is the ideal technology partner for Syneos Health,” said Michelle Keefe, CEO, Syneos Health. “Their clear industry leadership in AI and their pragmatic approach to improving healthcare outcomes for patients, science and industry is completely aligned with our value proposition.”

By creating a platform that makes use of the Azure cloud computing platform, as well as leveraging developments by OpenAI, Syneos’ goal is to analyze data to fast-track timelines, optimize resource allocation and unlock clinical trial efficiencies. The company said this will potentially allow new therapies to come to market faster.

Microsoft has been inking several deals in the API space with major manufacturers, including Novo Nordisk, who will be paying for its AI to speed up drug development.

Connect

Inside The Story

Syneos Health

About Joe Palmisano

Joe Palmisano is Editorial Director for Connect Money, where he brings nearly three decades experience of market insights as a financial journalist, analyst and senior portfolio manager for leading financial publications, advisory firms, and hedge funds. In his role as Editorial Director, Joe is responsible for the selection of content and creation of daily business news covering the financial markets, including Alternative Assets, Direct Investment and Financial Advisory services. Before joining Connect Money, Joe was a financial journalist for the Wall Street Journal, regularly publishing feature stories and trend pieces on the foreign exchange, global fixed income and equity markets. Joe parlayed his experience as a financial journalist into roles as a Senior Research Analyst and Portfolio Manager, writing daily and weekly market analysis and managing a FX and US equity portfolio. Joe was also a contributing writer for industry magazines and publications, including SFO Magazine and the CMT Association. Joe earned a B.S.B.A. in Finance from The American University. He holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.

New call-to-action
New call-to-action